Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials

Daniëlle M Gerlag; Paul P Tak

doi:10.1016/j.berh.2008.02.002

Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials

Best Pract Res Clin Rheumatol. 2008 Apr;22(2):311-23. doi: 10.1016/j.berh.2008.02.002.

Authors

Daniëlle M Gerlag¹, Paul P Tak

Affiliation

¹ Division of Clinical Immunology and Rheumatology, Academic Medical Centre/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

PMID: 18455687
DOI: 10.1016/j.berh.2008.02.002

Abstract

The analysis of synovial biomarkers is increasingly used in the context of innovative trial design in rheumatoid arthritis (RA). This approach, which is generally well tolerated by patients, has been used to provide insight into the pathogenesis of RA and the mechanism of action of therapy, as well as for screening purposes during early drug development.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / immunology
Biomarkers
Chemokines / drug effects
Humans
Rituximab
Synovial Membrane / drug effects*
Synovial Membrane / immunology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents
Biomarkers
Chemokines
Tumor Necrosis Factor-alpha
Rituximab